🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

52 results for “sars-cov-” Clear

  1. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  2. Azvudine

    Shanghai Henlius Biotech

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  3. Evolocumab

    COLLEGIUM PHARMACEUTICAL, INC

    Sars-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  4. METFORMIN, COLCHICINE

    Disc Medicine

    PASC: post-acute sequelae of SARS-CoV-2 infection

    phase 3 small molecule active

    1 trial

  5. METFORMIN, COLCHICINE, MINOCYCLINE, Placebo tablets are identical to active minocycline tablets and will be relabelled identical to the study drug. Placebo tablets will have the same composition, except for the active substance. (microcrystalline cellulose, magnesium stearate).

    Disc Medicine

    PASC: post-acute sequelae of SARS-CoV-2 infection

    phase 3 small molecule active

    1 trial

  6. Molnupiravir Matching placebo tablets, molnupiravir

    Merck Sharp and Dohme

    SARS-CoV-2 (COVID-19) infection

    phase 3 small molecule active

    1 trial

  7. NIRMATRELVIR, NIRMATRELVIR, Ritonavir, nirmatrelvir / ritonavir

    Pfizer Australia Pty Ltd

    SARS-CoV-2 Infection

    phase 3 small molecule active

    1 trial

  8. Nanocovax

    Biotech Pharmaceutical Co.,

    SARS-CoV-2 Infection

    phase 3 mab completed

    1 trial

  9. Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

    Livzon Pharmaceutical Group

    COVID-19 Pandemic

    phase 3 mab active

    1 trial

  10. S-217622

    Shionogi B.V.

    SARS-CoV-2 Infection

    phase 3 small molecule completed

    1 trial

  11. S-268019-b

    Shionogi B.V.

    SARS-CoV-2

    phase 3 small molecule completed

    1 trial

  12. SARS-CoV-2 Vaccine (Vero Cell), Inactivated

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19 Pneumonia

    phase 3 mab completed

    1 trial

  13. SARS-CoV-2 inactivated vaccine

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  14. SARS-CoV-2 mRNA Vaccine

    Biotech Pharmaceutical Co.,

    COVID-19

    phase 3 mab active

    1 trial

  15. SARS-CoV-2 vaccine (inactivated)

    Sinovac Research and Development Co.,

    SARS-CoV2 Infection

    phase 3 mab completed

    1 trial

  16. Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

    Sinovac Research and Development Co.,

    Covid19

    phase 3 mab completed

    1 trial

  17. ARCT-021

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab terminated

    1 trial

  18. ARCT-021 Dose 1

    Arcturus Therapeutics Holdings

    SARS-CoV-2

    phase 2 mab completed

    1 trial

  19. Drug COVID19-0001-USR

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 2 small molecule active

    1 trial

  20. Hyperimmune plasma

    Lxo Ireland Designated Activity Company

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  21. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  22. SARS-CoV-2 convalescent plasma

    United Therapeutics Europe Ltd

    SARS-CoV 2

    phase 2 mab completed

    1 trial

  23. SARS-CoV-2 mRNA Vaccine ARCT-021

    Arcturus Therapeutics Holdings

    Hematopoietic and Lymphatic System Neoplasm

    phase 2 mab active

    1 trial

  24. TAK-019

    Takeda

    Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)

    phase 2 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources